QLT Inc. Announces First Patient Dosed In Phase 2a Proof-Of-Concept Trial For QLT091001 In Impaired Dark Adaptation

Published: Dec 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, Dec. 9, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced that the first patient has been dosed in the Company's Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation (IDA), a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights.

Help employers find you! Check out all the jobs and post your resume.

Back to news